3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease
1
Dendritic Cell Sarcoma, Interdigitating
1
Burkitt Lymphoma
1
Brain Neoplasms
1
Interventions
Temozolomide
51
Bevacizumab
23
Radiotherapy
16
Magnetic Resonance Spectroscopy
16
Irinotecan
15
Carmustine
12
Erlotinib Hydrochloride
10
Carboplatin
8
Surgical Procedures, Operative
6
O(6)-benzylguanine
6
Imatinib Mesylate
6
Filgrastim
6
Cyclophosphamide
6
Biopsy
6
sargramostim
5
aldesleukin
5
X-Rays
5
Thalidomide
5
Phantoms, Imaging
5
Chemotherapy, Adjuvant
5
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
5
temsirolimus
4
Topotecan
4
Specimen Handling
4
Sirolimus
4
Radiation
4
Peripheral Blood Stem Cell Transplantation
4
Nuclear Medicine Department, Hospital
4
Etoposide
4
Cisplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
Antibodies, Monoclonal
×
Sarcoma
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled